Immunotherapy is uniquely positioned to shift the paradigm of cancer treatment. Cancer cells evade immune destruction in part by generating an immunosuppressive microenvironment. One immunotherapeutic approach to cancer treatment is adoptive tumor-infiltrating lymphocyte (TIL) therapy, in which T cells isolated from tumors are expanded in vitro and then reinfused into the patient to treat other tumors and distant metastases. The most responsive T cells are activated chronically and therefore succumb to a persistent hypo-responsiveness deemed T cell ‘exhaustion.’ As the most reactive to tumor antigens, exhausted T cells are the most desirable for expansion. However, the tumor-infiltrating T cells within the tumor microenvironment that would be crucial to an effective immune response instead display crippling metabolic defects characterized by loss of mitochondrial function and proliferate less vigorously compared to non-tumor-reactive T cells. Thus, most patients derive little benefit from this approach. The metabolic exhaustion of tumor-specific T cells is a significant barrier to adoptive TIL effectiveness, but metabolic reprogramming with pharmacologic agents may represent a solution.